Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
RMD Open|November 23, 2022
Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entryBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
RMD Open|January 6, 2021
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registryBente Glintborg, Dorte Vendelbo Jensen, Sara Engel, et al.
The Journal of Rheumatology|June 15, 2022
Long-term Behavioral Changes During the COVID-19 Pandemic and Impact of Vaccination in Patients With Inflammatory Rheumatic DiseasesBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
Annals of the Rheumatic Diseases|April 30, 2021
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trialHafsah Nabi, Stylianos Georgiadis, Anne Gitte Loft, et al.
Rheumatology (Oxford, England)|June 19, 2021
Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritisBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
RMD Open|March 15, 2024
Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trialSigne Møller-Bisgaard, Kim Hørslev-Petersen, Lykke Midtbøll Ørnbjerg, et al.
RMD Open|November 23, 2022
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registryHafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, et al.
Annals of the Rheumatic Diseases|November 7, 2018
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registryBente Glintborg, Anne Gitte Loft, Emina Omerovic, et al.
The Journal of Rheumatology|December 3, 2016
Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO RegistryBente Glintborg, Inge J Sørensen, Mikkel Østergaard, et al.
Annals of the Rheumatic Diseases|May 6, 2017
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryBente Glintborg, Inge Juul Sørensen, Anne Gitte Loft, et al.
Pageof 6